The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Critical Challenges in PD: Translating Genetic Findings Into, 2007Impact of Post-Translational Modifications on the Neurotoxicity of Alpha-Synuclein in Parkinson's Disease
Objective/Rationale:
The loss of neurons in the brains of Parkinson’s disease patients may be caused by harmful clusters or ‘aggregates’ of alpha-synuclein, an abundant protein in the central nervous... -
Critical Challenges in PD: Translating Genetic Findings Into, 2007Genetic Dissection of LRRK2 Domains Critical For Pathogenesis via BAC Transgenic Approach
Objective/Rationale:
Mutations in the LRRK2 gene are responsible for certain types of familial Parkinson’s disease. The protein product of the LRRK2 gene has a complex structure and to date, research... -
Critical Challenges in PD: Translating Genetic Findings Into, 2007Delivery of Kinase-Modified LRRK2 to Dopaminergic Neurons Using High-Capacity Viral Vectors
Objective/Rationale:
Mutations in the LRRK2 gene unambiguously associate with the development of late-onset Parkinson’s disease that mimics clinical and neurochemical features typical of the disease... -
Critical Challenges in PD: Translating Genetic Findings Into, 2007Using BAC Transgenic Mice to Determine Causative Role of LRRK2 Kinase Activity in PD Pathogenesis
Objective/Rationale:
Emerging evidence has implicated kinase activity of LRRK2, the PD. The objective of this project is to use novel animal models to determine whether enhanced LRRK2 kinase activity... -
Critical Challenges in PD: Translating Genetic Findings Into, 2007Viral Gene Delivery for the In Vivo Expression of PD-Causing LRRK2 Mutant Proteins
Objective/Rationale:
LRRK2 is a human gene encoding a protein kinase whose normal function in healthy subjects is still unknown. However, mutations in the LRRK2 gene have recently been recognized as... -
Therapeutics Development Initiative, 2007Development of Drugs Preventing Mitochondrial Dysfunction to Treat PD
Objective/Rationale:
Parkinson’s dsease is caused by the death of brain dopaminergic neurons that are essential for controlling movement. While the exact cause of PD is not known, there is evidence...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.